Strategic Partnerships Tollo Health is connected to Todos Medical and recently expanded through the Provista Diagnostics acquisition, signaling potential for joint sales initiatives in cancer screening and CLIA/CAP laboratory services across US and international markets.

Clinical Diagnostics With CE-marked cancer screening tests and ongoing development of neurodegenerative tests, there are cross-selling opportunities to hospital systems, clinics, and diagnostic laboratories seeking comprehensive blood-based screening portfolios.

Lab Services Access Acquisition of Provista Diagnostics provides access to a CLIA/CAP certified lab and PCR testing capabilities, enabling faster pilot programs, validation studies, and potential contract manufacturing or testing partnerships.

Early Detection Focus Target institutions prioritizing early cancer and neurodegenerative detection can be engaged for pilot deployments of TBIA-based tests and LymPro, leveraging demonstrated immune-system insights and peripheral blood biomarkers.

Strategic Funding Revenue and modest funding levels indicate room for co-development deals, sponsored research, and grant-supported programs with healthcare providers and biotech firms aiming to expand diagnostic offerings.